NASDAQ:EPZM - Epizyme Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $11.60 +0.16 (+1.40 %) (As of 03/25/2019 04:00 PM ET)Previous Close$11.44Today's Range$11.20 - $11.6952-Week Range$5.14 - $19.55Volume377,363 shsAverage Volume978,024 shsMarket Capitalization$1.05 billionP/E Ratio-6.74Dividend YieldN/ABeta3.15 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Epizyme, Inc., a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function; and Phase II clinical trial for adults and Phase I clinical trial for children with epithelioid sarcoma and other INI1-negative solid tumors. It also develops tazemetostat in combination with R-CHOP that is in the Phase Ib/II clinical trials in elderly patients with DLBCL; and tazemetostat in combination with PD-L1 inhibitor, which is in the Phase Ib/II clinical trials for the treatment of patients with relapsed or refractory metastatic non-small cell lung cancer. In addition, the company is developing EZM8266, a G9a inhibitor that is in the Phase 1 study for the treatment of sickle cell disease; pinometostat, which is in the preclinical studies stage for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; PRMT5 inhibitor that is in Phase II clinical trial for patients with solid tumors and NHL; and PRMT1 inhibitor, which is in the Phase 1 clinical trial. Epizyme, Inc. has collaboration agreements with Celgene Corporation; Genentech Inc.; Glaxo Group Limited; Boehringer Ingelheim International GmbH; Roche Molecular Systems, Inc.; Lymphoma Study Association; and Eisai Co. Ltd. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts. Receive EPZM News and Ratings via Email Sign-up to receive the latest news and ratings for EPZM and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EPZM Previous Symbol CUSIPN/A CIK1571498 Webwww.epizyme.com Phone617-229-5872Debt Debt-to-Equity RatioN/A Current Ratio7.20 Quick Ratio7.20Price-To-Earnings Trailing P/E Ratio-6.74 Forward P/E Ratio-5.32 P/E GrowthN/A Sales & Book Value Annual Sales$21.70 million Price / Sales48.50 Cash FlowN/A Price / Cash FlowN/A Book Value$2.94 per share Price / Book3.95Profitability EPS (Most Recent Fiscal Year)($1.72) Net Income$-123,630,000.00 Net MarginsN/A Return on Equity-58.76% Return on Assets-50.56%Miscellaneous Employees124 Outstanding Shares90,730,000Market Cap$1.05 billion Next Earnings Date5/14/2019 (Estimated) OptionableOptionable Epizyme (NASDAQ:EPZM) Frequently Asked Questions What is Epizyme's stock symbol? Epizyme trades on the NASDAQ under the ticker symbol "EPZM." How were Epizyme's earnings last quarter? Epizyme Inc (NASDAQ:EPZM) issued its earnings results on Tuesday, February, 26th. The biopharmaceutical company reported ($0.29) EPS for the quarter, beating the Zacks' consensus estimate of ($0.46) by $0.17. View Epizyme's Earnings History. When is Epizyme's next earnings date? Epizyme is scheduled to release their next quarterly earnings announcement on Tuesday, May 14th 2019. View Earnings Estimates for Epizyme. What price target have analysts set for EPZM? 8 brokerages have issued twelve-month price targets for Epizyme's stock. Their predictions range from $11.00 to $25.00. On average, they expect Epizyme's share price to reach $18.50 in the next twelve months. This suggests a possible upside of 59.5% from the stock's current price. View Analyst Price Targets for Epizyme. What is the consensus analysts' recommendation for Epizyme? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Epizyme in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Epizyme. Has Epizyme been receiving favorable news coverage? Headlines about EPZM stock have trended somewhat negative recently, according to InfoTrie. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Epizyme earned a daily sentiment score of -1.1 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the next few days. Are investors shorting Epizyme? Epizyme saw a increase in short interest in the month of February. As of February 15th, there was short interest totalling 5,712,083 shares, an increase of 31.5% from the January 31st total of 4,345,330 shares. Based on an average daily volume of 775,401 shares, the short-interest ratio is currently 7.4 days. Currently, 9.9% of the company's stock are short sold. View Epizyme's Current Options Chain. Who are some of Epizyme's key competitors? Some companies that are related to Epizyme include TESARO (TSRO), HUTCHISON CHINA/S (HCM), ACADIA Pharmaceuticals (ACAD), Evotec (EVTCY), Agios Pharmaceuticals (AGIO), Blueprint Medicines (BPMC), Ultragenyx Pharmaceutical (RARE), Intercept Pharmaceuticals (ICPT), Amicus Therapeutics (FOLD), Global Blood Therapeutics (GBT), Mirati Therapeutics (MRTX), Reata Pharmaceuticals (RETA), Ligand Pharmaceuticals (LGND), Akcea Therapeutics (AKCA) and Emergent Biosolutions (EBS). What other stocks do shareholders of Epizyme own? Based on aggregate information from My MarketBeat watchlists, some companies that other Epizyme investors own include Micron Technology (MU), Synergy Pharmaceuticals (SGYP), Verastem (VSTM), Array Biopharma (ARRY), Gilead Sciences (GILD), ACADIA Pharmaceuticals (ACAD), Insys Therapeutics (INSY), Omeros (OMER), Novavax (NVAX) and Incyte (INCY). Who are Epizyme's key executives? Epizyme's management team includes the folowing people: Mr. Robert B. Bazemore Jr., Pres, CEO, Sec. & Director (Age 51)Mr. Matthew E. Ros, Chief Strategy & Bus. Officer and Principal Financial Officer (Age 52)Dr. H. Robert Horvitz, Co-Founder & Chairman of the Scientific Advisory BoardDr. Yi Zhang, Scientific Co-Founder & Member of The Scientific Advisory BoardMr. Joseph Beaulieu, Controller, Treasurer & Principal Accounting Officer (Age 38) Who are Epizyme's major shareholders? Epizyme's stock is owned by a variety of of institutional and retail investors. Top institutional investors include NEA Management Company LLC (8.69%), BlackRock Inc. (6.56%), FMR LLC (4.39%), Jennison Associates LLC (2.37%), Foresite Capital Management II LLC (1.97%) and Norges Bank (1.43%). Company insiders that own Epizyme stock include Andrew E Singer, David M Mott, Matthew Ros, Peter Tai-Ching Ho and Robert A Copeland. View Institutional Ownership Trends for Epizyme. Which major investors are selling Epizyme stock? EPZM stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, FMR LLC, Tekla Capital Management LLC, Eversept Partners LP, New York State Common Retirement Fund, MetLife Investment Advisors LLC and Barclays PLC. View Insider Buying and Selling for Epizyme. Which major investors are buying Epizyme stock? EPZM stock was acquired by a variety of institutional investors in the last quarter, including Norges Bank, Opaleye Management Inc., BlackRock Inc., Millennium Management LLC, NEA Management Company LLC, Sphera Funds Management LTD., Dimensional Fund Advisors LP and Dimensional Fund Advisors LP. View Insider Buying and Selling for Epizyme. How do I buy shares of Epizyme? Shares of EPZM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Epizyme's stock price today? One share of EPZM stock can currently be purchased for approximately $11.60. How big of a company is Epizyme? Epizyme has a market capitalization of $1.05 billion and generates $21.70 million in revenue each year. The biopharmaceutical company earns $-123,630,000.00 in net income (profit) each year or ($1.72) on an earnings per share basis. Epizyme employs 124 workers across the globe. What is Epizyme's official website? The official website for Epizyme is http://www.epizyme.com. How can I contact Epizyme? Epizyme's mailing address is 400 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-229-5872 or via email at [email protected] MarketBeat Community Rating for Epizyme (NASDAQ EPZM)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 373 (Vote Outperform)Underperform Votes: 279 (Vote Underperform)Total Votes: 652MarketBeat's community ratings are surveys of what our community members think about Epizyme and other stocks. Vote "Outperform" if you believe EPZM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EPZM will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/25/2019 by MarketBeat.com StaffFeatured Article: Trading Stocks - What are percentage gainers?